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ABSTRACT 
Objective: The purpose of this study was to compare the effect of famotidine versus omeprazole on the efficacy of calcium carbonate as a phosphate 
binder in the hemodialysis patient. 
Methods: From February 2014 to June 2014 a total number of 64 patients of both sexes were recruited from the department of renal dialysis, Tanta 
University Hospital, Egypt. Patients categorized into 3 groups. Group I (control group) consisted of 20 Patients (10) females and (10) males take 
calcium carbonate (caco3) (2.5–4 g/d) only, Group II consisted of 21 Patients (13) females and (8) males take the same dose of caco3 with 
famotidine 10 mg/d and Group III consisted of 23 Patients (8) females and (15) male take the same dose caco3
Results: All data are expressed as the mean±SD. Group II showed a significant increase (p<0.05) in serum phosphorus at 3
 with omeprazole 20 mg/d. 
rd
Conclusion: Co-administration of famotidine with calcium carbonate aggravates hyperphosphatemia and this may increase the incidence of 
complications. The efficacy of calcium carbonate as a phosphate binder was not affected by co-administration of omeprazole. 
 mo with significant decreased 
(p<0.05) in serum calcium comparing with pre-treatment. Group III showed no significant change (p>0.05) in serum calcium, phosphorus and parathyroid 
hormone (PTH) comparing with pre-treatment. Both groups (II and III) showed a significant decrease in alkaline phosphatase (ALP) (p<0.05). 
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End-stage renal disease (ESRD) is the complete or almost complete 
failure of the kidneys to work. Kidneys are no longer able to work 
at a level needed for d to d life. The most common causes of ESRD 
are diabetes and hypertension. ESRD detected as an increase in 
serum creatinine or proteinuria also, many signs and symptoms 
appear on the patient. Dialysis or kidney transplantation is the only 
treatment for this condition. 
Hyperphosphatemia is one of the main complications in ESRD 
patient. It is an electrolyte disturbance in which there is an 
abnormally elevated level of phosphate in the blood (5 mg/dL in 
adults and 7 mg/dL in children or adolescents) caused by many 
causes include chronic kidney disease. It is associated with high 
mortality risk [1]. Typically, most patients with hyperphosphatemia 
are asymptomatic. However, patients occasionally report 
hypocalcemic symptoms. More commonly, patients report 
symptoms related to the underlying cause of hyperphosphatemia. 
Serious effect on the person’s nervous and cardiovascular system 
[2, 3]R Rmay occur. Complications include ectopic calcification [4, 5], 
secondary hyperparathyroidism [4]R Rand renal osteodystrophy.  
Treatment includes a diet low in phosphate and use of phosphate 
binder including calcium-containing phosphate binder which most 
commonly used [6]. The primary goal of treatment is to reduce 
serum phosphorus to normal levels in patients with stage 3-5 
chronic renal failure (CRF) and to 5.5 mg/dL or less in patients with 
stage 5D CRF [7]. 
In chronic renal failure and particularly in ESRD, upper 
gastrointestinal bleeding from gastroduodenal ulcers, erosive 
gastritis or esophagitis by gastroesophageal reflux is frequent. The 
use of inhibitors of gastric acid secretion is the base for the 
preventive or curative treatment of these complications, even if the 
gastric hyperacidity induced by hypergastrinemia due to renal 
failure is not constant. Patients on dialysis usually have fragile 
gastrointestinal tract and gastrointestinal symptoms [8]. These 
patients usually use proton pump inhibitor or H2-receptor 
antagonist. 
Metallic phosphate binders require acidity to dissociate to the free 
metallic ion and bind phosphorus. Altered gastric acidity may, 
therefore, influence phosphate-binding efficacy [9]. 
The objective of this study was to compare the effect of famotidine 
versus Omeprazole on the efficacy of calcium carbonate as a 
phosphate binder in the hemodialysis patient. 
MATERIALS AND METHODS 
Study design 
Randomized, prospective, controlled, open-labeled study was used 
included sixty-four Patients of both sexes from the department of 
renal dialysis, Tanta University Hospital, Egypt. 
This study was approved by the Research Ethics Committee of 
Faculty of Pharmacy-Tanta University (REC-FPTU). Written 
consents from all patients enrolled in the study were obtained. 
From patient history, these patients were categorized into three 
groups; Group I (control group) consisted of 20 Patients (10) 
females and (10) males take cacoR3R only, Group II consisted of 21 
Patients (13) females and (8) males take the same dose of cacoR3R 
with famotidine 10 mg/d and Group III consisted of 23 Patients (8) 
females and (15) male take the same dose cacoR3R with omeprazole 
20 mg/d. All patients received their medications for 4 mo.  
Blood samples were collected before the study and then monthly 
during the study for four mo during hemodialysis sessions for 
serum phosphate, calcium, ALP and PTH levels. There is no change 
in dialysis schedule during the study period (Time, frequency, 
dialysate calcium content or filter). 
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• ESRD patients treated with calcium carbonate alone as a 
phosphate binder. 
• The presence of ESRD during dialysis periods with phosphorus 
levels>5.5 mg/dL. 
• Patients should be on a diet low in phosphorus. 
• Receiving three times weekly hemodialysis more than 6 mo. 
• Male and female patients will be included. 
Exclusion criteria 
The patient will be excluded if there is evidence of:  
• Active peptic ulcer, recent gastrointestinal bleeding or major 
oesophagal reflux. 
• Severe hyperparathyroidism. 
• Hypercalcemia. 
• Treatment with vitamin D analogs. 
• Smoking 
Specifications of drugs  
Calcium carbonate manufactured by the elnasr pharmaceutical 
company, abozabal, Cairo, Egypt. 
Famotidine manufactured by amoun pharmaceutical company, el-
obour city, Cairo, Egypt. 
Omeprazole manufactured by elfaronia pharmaceutical company, 
masr elgededa, Cairo, Egypt. 
Laboratory analyses 
Sample collection  
Blood sampling was performed at the start of the study and then 
monthly for four mo during the hemodialysis sessions. Five ml 
blood was collected from the antecubital vein into sterile tubes, 
then centrifugated immediately with 3000 x g for 10 min to 
separate sera, then biochemical analyses were done for serum 
phosphate, calcium, alkaline phosphates and PTH levels.  
Assay 
1-Serum calcium level was measured on Microlab 200 (MERCK 
Instrument Inc.; Scientific Instrument Division, Germany) by using 
kits supplied by STANBIO laboratories (USA). Using a colorimetric 
assay according to the method of Stern and Lewis., 1957; Sarkar 
and Chauhan., 1967 [10, 11]. 
2-Inorganic serum phosphorus was measured on Microlab 200 
(MERCK Instrument Inc.; Scientific Instrument Division, Germany) by 
using kits supplied by STANBIO laboratories (USA). Using a 
spectrophotometric assay according to the method of Fiske and 
Subbarow., 1925; Goodwin, 1970 [12, 13]. 
3-Serum ALP was measured on Microlab 200 (MERCK Instrument 
Inc.; Scientific Instrument Division, Germany) by using kits 
supplied by STANBIO laboratories (USA). Using a kinetic method 
according to the method of Fujita 1939; Bowers and McCOMBR., 
1966 [14, 15]. 
4-Serum PTH was assayed on VIDAS Multiparametric immune 
analyzer (Biomerieux Inc.; Scientific Instrument Division, Marcy 
l'Etoile, France) by using VIDAS kit supplied by BIOMERIEUX 
laboratories (France) using a double sandwich technique according 
to the method of Armitage; 1986; Kao et al., 1992 [16, 17]. 
Statistical analysis 
All data are expressed as the mean±SD. The mean values of each 
group compared with the pretreatment mean values using paired 
student t-test and the mean values of the three groups compared 
using one-way ANOVA followed by Tukey's test using a level of 
significance of *p<0.05. Statistical significance will be carried out 
using SPSS Software for windows version 20 (2011). 
RESULTS 
A total number of 64 patients of both sexes were recruited from the 
department of renal dialysis, Tanta University Hospital, Egypt. 
Patients categorized into 3 groups. Group I (control group) 
consisted of 20 Patients (10) females and (10) males take caco3  
only, Group II consisted of 21 Patients (13) females and (8) males 
take the same dose of caco3 with famotidine 10 mg/d and Group III 
consisted of 23 Patients (8) females and (15) male take the same 
dose caco3
The biochemical of group I throughout the study are shown in table 
2. Paired student t-test was carried out for each parameter between 
the baseline results and the results of each mo post treatment. 
There were no significant changes in the four parameters 
throughout the study (p>0.05). 
 with omeprazole 20 mg/d. 
The demographic characteristics were shown in table 1. As seen 
from table 1, no significant differences between the three studied 
groups in age, sex, and duration of dialysis (p>0.05). 
 
Table 1: It shows the demographic characteristics of the three studied groups 
Characteristics Group I  




 group) (N =21) (omeprazole/caco3 group)(N =23) 
Age 52.71±9.61 47.19±12.1 46.56±10.2 
Sex Male 10 8 15 
Female 10 13 8 
Duration of dialysis 
(mo) 
92.8±22.6 94.2±20.71 92.08±23.4 
-Data are represented as mean±SD, -N, Number of patients 
 
Table 2: It shows Group I (control group) biochemicals throughout the study 
Parameters Phosphorus level (mg/dl) Calcium level (mg/dl) ALP level (mg/dl) PTH level(Pg/ml) 
Interval 
Baseline 5.69+0.87 9.71+0.57 96.88+33.4 151.8+49.2 
1st 5.75+0.84 mo post treatment 8.04+0.99 89.41+27.1 156+46.3 
2nd 5.80+0.63  mo post treatment 7.85+0.75 88.92+12.37 161+38.2 
3rd 5.99+0.89  mo post treatment 8.31+0.74 86.52+8.36 168+44.6 
4th 6.03+0.69  mo post treatment 8.36+0.69 85.24+9.62 170+58.6 
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The biochemical of group II throughout the study are shown in 
table 3. Paired student t-test was carried out for each 
parameter between the baseline results and results of each mo 
post treatment shown a significant increase in serum 
phosphorus level from the baseline occurred in 3rd and 4th mo of 
treatment this augmented by a significant decrease in serum 
calcium level in the same mo. Also, there was a significant 
decrease in serum ALP level from baseline at the 4th
 
 mo of 
treatment, while no significant change occurred in serum PTH 
throughout the study (p>0.05). 
Table 3: It shows group II (famotidine/caco3
Parameters 
) group biochemicals throughout the study 
Phosphorus level (mg/dl) Calcium level (mg/dl) ALP level (mg/dl) PTH level (Pg/ml) 
Interval 
Baseline 5.12+0.71 8.79+0.89 90.25+12.36 145.1+53.6 
1st 5.52+0.86 mo post treatment 7.65+0.77 85.6+16.2 155.1+45.6 
2nd 6.79+0.91  mo post treatment 7.38+0.69 76.29+13.7 191.5+39.2 
3rd 7.43+0.74 mo post treatment 6.24+0.85* 62.21+8.63 * 195.6+41.2 
4th 7.63+0.69 mo post treatment 6.33+0.71* 55.9+10* 196.9+55.8 * 
*
 
 Significant difference from baseline (p<0.05)  
The biochemicals of group III throughout the study are shown in 
table 4. Paired student t-test carried out for each parameter 
between the baseline results and results of each mo post treatment 
shown a significant decrease in serum ALP level at the 4th
 
 mo of 
treatment no significant changes occurred in other three 
parameters (p>0.05). 
Table 4: It shows Group III (omeprazole/caco3
Parameters 
) group biochemicals throughout the study 
Phosphorus level (mg/dl) Calcium level (mg/dl) ALP level (mg/dl) PTH level(Pg/ml) 
Interval 
Baseline 5.05+0.84 9.25+0.69 92.51+16.7 173.6+49.5 
1st 5.16+0.76 mo post treatment 8.69+0.58 88.47+16.3 188+50.2 
2nd 6+0.94  mo post treatment 7.36+0.91 85.44+5.13 186+44.6 
3rd 5.15+0.73  mo post treatment 8.36+0.91 85.44+5.13 190+53.2 
4th 5.15+0.55  mo post treatment 8.62+0.74 68.13+9.52 192+51.6 * 
*
 
 Significant difference from baseline (p<0.05) 
Serum phosphorus level in the three studied groups compared by 
ANOVA showed that in 3rd and 4th mo serum phosphorus levels were 
higher in group II than group I at 3rd mo (7.43+0.74) versus 
(5.99+0.89) with p =0.039 and 4th
  
 mo (7.63+0.69) versus (6.03+0.69) 
with p =0.024 respectively, with no significant change in group III than 
group I and group II at baseline and throughout the study. (fig. 1). 
 
Fig. 1: Shows serum phosphorus level mean+SD value (mg/dl) in 3 studied groups at baseline (February) and each mo along the study 
-N in GI = 20, GII = 21 and GIII = 23, -Significant increase in GII phosphorus compared with GI with no change in GIII  
 
Serum calcium level in the three studied groups compared by 
ANOVA showed that hyperphosphatemia in group II augmented 
by the significant decrease in serum calcium level in group II 
more than group I (6.24+085) versus (8.31+0.74) at 3rd mo post 
treatment and (6.33+0.71) versus (7.36+69) at 4th
Serum ALP in the three studied groups compared by ANOVA 
showed that there was a significant decrease in the ALP level in 
group II and group III than group I at 4
 mo post 
treatment with p-value 0.039 and 0.024 respectively No 
significant difference in group III from group I and II along the 
study. 
th
Serum PTH in the three studied groups compared by ANOVA 
showed that there are no significant changes between the three 
groups along the study (p>0.05). 
-mo post treatment with p-
value 0.047 and 0.042 respectively. 
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Also, we did clinical questioner to the patients of the three groups 
to show change in levels of itching as an indication of 
hyperphosphatemia control while increased level of itching is 
indication of poor hyperphosphatemia control and from this we 
showed that group II showed increasing of patients complain of 
itching from mo to mo comparing to groups I and III. (fig. 2).  
 
 
Fig. 2: shows number of patients complained of itching at the 
baseline mo (February) and then each mo throughout the 
study 
 
In clinical questioner, we also asked the patients of the three 
groups about improvement in GIT problem (flatulence, 
hyperacidity, gastroesophageal reflux, etc) and group III showed a 
decrease in a number of patients with GIT problems from mo to mo 
more than group II and group I. 
DISCUSSION 
Mineral metabolism derangements occur during the early stages of 
chronic kidney disease (CKD). Phosphorus serum levels are usually 
within normal range until the GFR falls below 30 ml/min according 
to the National Kidney Foundation Kidney Disease Outcomes 
Quality Initiative classification.  
Although some studies showing the effect of co-administration of 
either famotidine or omeprazole with caco3
In the present study, it has been found that the regular use of 10 mg 
once daily of famotidine (the recommended dose for hemodialysis 
patients) with caco
 there is no data 
compare between both combinations regarding the effect on 
hyperphosphatemia. 
3  for 4 mo worsens the hyperphosphatemia in 
chronic renal failure patients on hemodialysis. These data agree 
with Matsunaga C, et al. who studied the effect of famotidine (10 
mg/d) and lansoprazole on serum phosphorus levels in 
hemodialysis patients on caco3  therapy on 115patients with ESRD 
in crossover protocol, not parallel [18]
These effects explained by Takahashi et al. they reported that the 
phosphate binding properties of calcium carbonate depend on 
gastric acid. Gastric hydrochloric acid increases the solubility of 
calcium carbonate providing more free calcium ions for binding of 
phosphate and it is responsible for the partial conversion of 
calcium carbonate to calcium chloride [19]. 
. 
In the present study, famotidine aggravated the condition of the 
patients by augmenting hypocalcaemia state after 4 mo. This effect is 
supported by Goss et al., 2007 who explained that at neutral pH, 
calcium carbonate is practically insoluble in water, but although the 
solubility of calcium salts may be highly pH dependent, calcium 
absorption is unaffected by alterations in gastric acid secretion [20]
In this study, it has also been found that famotidine with caco
. 
3  did 
not show any significant change in serum PTH, which contradicted 
by the study of Bricker, who suggested that original proposal was 
that phosphate retention as a result of reductions in glomerular 
filtration rate would cause transient decreases in the levels of 
calcium, which would, in turn, trigger an increase in PTH secretion 
and a new steady state would be achieved, with restoration of 
normal calcium and phosphate levels but, with the consequence 
that high levels of PTH now would be required to maintain 
homeostasis [21]
The present study shows a significant decrease in serum ALP level 
upon administration of famotidine in combination with caco
. 
3; this 
is in agreement with Kinjo et al. who reported that long-term use of 
H2-receptor antagonists result in a slight reduction in bone mineral 
density [22]
Regular omeprazole co-administration with caco
. 
3
Further support of our study is found in the study of Osler et al. 
who concluded that omeprazole augmented the phosphate binding 
capacity of calcium carbonate in six normal subjects [24]. 
 in the present 
study produced no significant change in the serum phosphorus 
level. Hardy et al. reported no significant difference in the control of 
phosphatemia in 16 patients on chronic hemodialysis [23]. 
In uremic patients, plasma phosphate levels are dependent on the 
transmembrane shift of intracellular phosphate toward the 
extracellular compartment with acidosis and on the plasmatic 
physicochemical inverse equilibrium of plasma phosphate and 
calcium beside the intestinal absorption of phosphate. 
Our data are contradicting with that of Graziani et al. who found 
that the stimulating effect of gastric secretion on Po4
In group III serum calcium showed no change from control group 
values. This effect is contradicted by Carr and Shangraw they 
reported that daily omeprazole increased the median stomach pH 
and that the corrected calcemia was significantly lower under 
omeprazole [26]. 
 intestinal 
absorption would be due to better solubilization of dietary 
phosphate for which passive absorption by the duodenum is 
facilitated in its acid form the rest of the phosphate absorption in 
its basic form taking place more distally under the control of 
calcitriol [25]. 
The decrease in calcemia with omeprazole had already been 
observed by Straub, who found that the use of (PPIs) decrease basal 
and maximal outputs of acid, and will, therefore, diminish the 
quantity of acid available for the dissociation of calcium salts 
postprandially [27]. This may be due to the explanation of Yang and 
Metz. They reported that in the stomach, the systemically absorbed 
PPIs are delivered to the basolateral surface of the parietal cell. 
They are weak bases diffuse through the cytoplasm of the cell into 
the secretory canaliculus. This secretory canaliculus is acidic with a 
pH of less than 4.0 such that the weakly basic drug undergoes 
protonation and is then trapped in this acidic compartment so 
calcium can be absorbed in the duodenum even in the absence of 
gastric dissociation because the duodenal brush border locally 
produces an acid environment [28]. 
No change in serum PTH level our results which coincide with 
Hardy et al. [23] . 
Our data showed a significant decrease in serum ALP level upon 
combining omeprazole with caco
While the results are contradicted by the findings 
of Mizunashi et al. who suggested that omeprazole treatment is 
associated with elevated concentrations of PTH in the circulation 
but, it is not clear whether this resulted directly from gastrin-
mediated hyperplasia of parathyroid gland [29]. 
3
The authors own view for the reason that caco
. Hilliard et al. demonstrated that 
endogenous phosphate interferes with the determination of 
alkaline phosphates in urine and suggested that the wide variation 
in serum inorganic phosphate concentrations in diseases such as 
renal tubular disease or uremia might interfere with alkaline 
phosphatase measurements in serum [30]. 
3  efficacy not 
affected by co-administration of omeprazole compare to co-
administration of famotidine is that omeprazole augmented the 
phosphate binding capacity of calcium carbonate due to greater 
intragastric binding of phosphorus by caco3 even if its dissociation 
were less because although generated in smaller amounts all the 
calcium ions would be captured by Po4 because fewer protons 
would be competing with them for phosphate binding while with 
famotidine it acts on stomach H2 receptors and not affect protons 
so, greater protons would be competing with calcium ions for 
phosphate binding and this effect caco3 efficacy. 
Aboelyazeed et al. 




Co-administration of famotidine with caco3
ACKNOWLEDGMENT 
 aggravates hyper-
phosphatemia and this may increase the incidence of 
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